# Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA

> **NCT02607553** · PHASE2 · COMPLETED · sponsor: **GenSpera, Inc.** · enrollment: 2 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** G-202

## Key facts

- **NCT ID:** NCT02607553
- **Lead sponsor:** GenSpera, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2016-12
- **Final completion:** 2017-02
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2017-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02607553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02607553, "Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT02607553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*